Log in to search using one of your social media accounts:

 

NICE recommends use of Janssen ’s Imbruvica for Waldenstr ö m ’s macroglobulinaemia
The National Institute for Health and Care Excellence (NICE) in the UK has recommended the use of Janssen Pharmaceutical ’s Imbruvica (ibrutinib) on the Cancer Drugs Fund (CDF) to treat adults with a type of   non-Hodgkin lymphoma called Waldenstr ö m ’s m… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 1, 2017 Category: Pharmaceuticals Source Type: news

Sunesis starts dosing in Phase Ib/II trial of SNS-062 for B-cell malignancies
Sunesis Pharmaceuticals has started dosing patients in a Phase Ib/II clinical trial of SNS-062 to treat patients with B-cell malignancies such as chronic lymphocytic leukaemia (CLL), small lymphocytic leukaemia, Waldenstrom ’s macroglobulinemia and ma… (Source: Drug Development Technology)
Source: Drug Development Technology - July 18, 2017 Category: Pharmaceuticals Source Type: news

Ibrutinib'Remarkable' in Waldenstrom's Macroglobulinemia Ibrutinib'Remarkable' in Waldenstrom's Macroglobulinemia
Single-agent ibrutinib is highly active in refractory Waldenstrom's macroglobulinemia, with results that'eclipse other treatment options,'says an editorialist.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 29, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Ibrutinib: Indication of added benefit in one of three therapeutic indications
No added benefit has been proven for chronic lymphocytic leukaemia and Waldenström macroglobulinaemia. Certain patients with relapsed or refractory mantle cell lymphoma benefit from the drug. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 2, 2016 Category: Science Source Type: news

Ibrutinib: Indication of added benefit in one of three therapeutic indications
(Institute for Quality and Efficiency in Health Care) No added benefit proven for chronic lymphocytic leukaemia and Waldenström macroglobulinaemia. Certain patients with relapsed or refractory mantle cell lymphoma benefit from the drug. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 2, 2016 Category: Global & Universal Source Type: news

Idera Pharmaceuticals Reports Positive Data From Ongoing Phase 1/2 Clinical Trial of IMO-8400 in Patients With Waldenstrom’s Macroglobulinemia
(Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - December 6, 2015 Category: Pharmaceuticals Source Type: news

CURE Media Group Adds International Waldenstrom’s Macroglobulinemia...
Partnership expands outreach and information for patients suffering from rare cancer.(PRWeb October 13, 2015)Read the full story at http://www.prweb.com/releases/CUREAdvocacy/IWMF/prweb13016892.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 14, 2015 Category: Pharmaceuticals Source Type: news

AbbVie’s Imbruvica obtains European approval to treat blood cancer WM
AbbVie has received marketing approval from the European Commission (EC) for its Imbruvica (ibrutinib) to treat patients with Waldenstrom's macroglobulinemia (WM), a rare and slow-growing blood cancer. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 12, 2015 Category: Pharmaceuticals Source Type: news

Ibrutinib Gets High Marks for Waldenstrom's Macroglobulinemia
(MedPage Today) -- Data supporting recent FDA approval appear in print. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 11, 2015 Category: Hematology Source Type: news

New Waldenstrom's drug shows sustained benefit at two years
Ibrutinib, a newly approved drug for Waldenstrom's Macroglobulinemia, continues to control the rare blood cancer, with 95 percent of patients surviving for two years, research concludes. The disease stems from an abnormality in B lymphocytes in the bone marrow causing them to overproduce IgM, an immunoglobulin protein that thickens the blood; patients may experience bleeding, dizziness, headaches, weight loss, bruising and nerve damage. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 9, 2015 Category: Science Source Type: news

New Waldenstrom's drug shows sustained benefit at two years
(Dana-Farber Cancer Institute) Dana-Farber researchers report in the New England Journal of Medicine that ibrutinib, a newly approved drug for Waldenstrom's Macroglobulinemia, continues to control the rare blood cancer, with 95 percent of patients surviving for two years. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 9, 2015 Category: Global & Universal Source Type: news

'New Era' in the Treatment of Rare Lymphoma'New Era' in the Treatment of Rare Lymphoma
Ibrutinib is the first drug approved for the treatment of Waldenström's macroglobulinemia, and new data strengthen its profile. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 8, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Genetics Home Reference: Waldenström macroglobulinemia
http://ghr.nlm.nih.gov/condition/waldenstrom-macroglobulinemia (Source: NLM General Announcements)
Source: NLM General Announcements - April 7, 2015 Category: Databases & Libraries Source Type: news

FDA Expands Imbruvica Use for Non-Hodgkin Lymphoma
Imbruvica (ibrutinib) can now be prescribed for patients with Waldenström’s macroglobulinemia (WM), a rare form of cancer that begins in the body’s immune system (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - February 4, 2015 Category: Pharmaceuticals Source Type: news

Ibrutinib Approved in US for Rare LymphomaIbrutinib Approved in US for Rare Lymphoma
This is the first drug ever to be approved for the treatment of Waldenstrom's macroglobulinemia since the disease was described 70 years ago. FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 30, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Janssen and Pharmacyclics receive FDA approval for Imbruvica to treat WM
Janssen Biotech and Pharmacyclics have received approval from the US Food and Drug Administration (FDA) for Imbruvica (ibrutinib) capsules as the first therapy indicated specifically for patients with Waldenström's macroglobulinemia (WM), a rare, ind… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - January 30, 2015 Category: Pharmaceuticals Source Type: news

FDA expands use of Imbruvica to treat rare form of blood cancer
(Reuters) - The U.S. Food and Drug Administration said it cleared an expanded use of Imbruvica to treat Waldenström's macroglobulinemia (WM), a rare form of blood cancer for which no specific pharmaceutical therapy exists. (Source: Reuters: Health)
Source: Reuters: Health - January 29, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

FDA expands approved use of Imbruvica for rare form of non-Hodgkin lymphoma
The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) for previously treated patients with Waldenström’s macroglobulinemia (WM), a rare form of cancer that begins in the body’s immune system. The drug received a breakthrough therapy designation for this use. (Source: Food and Drug Administration)
Source: Food and Drug Administration - January 29, 2015 Category: American Health Source Type: news

Cloning Variable Region Genes of Clonal Lymphoma Immunoglobulin for Generating Patient-Specific Idiotype DNA vaccines
Available therapies for lymphoplasmacytic lymphoma (LPL) provide no survival advantage if started before signs or symptoms of end-organ damage develop; hence, current recommendations are to follow a program of observation while patients are in the asymptomatic phase of disease. We hypothesize that using idiotypic determinants of a B-cell lymphoma’s surface immunoglobulin as a tumor-specific marker, we can develop patient-specific chemokine-idiotype fusion DNA vacciness that induce an immune response against LPL. By activating the host immune system against the tumor antigen, we postulate that disease control of asymp...
Source: Springer protocols feed by Cancer Research - April 7, 2014 Category: Cancer & Oncology Source Type: news

Discovery of CXCR4 mutations in Waldenstrom's Macroglobulinemia helps identify which patients are more likely to benefit from ibrutinib
In nearly one-third of patients with Waldenstrom's Macroglobulinemia, a specific genetic mutation switches on the disease, and a new drug that blocks the defective gene can arrest the disease in animal models, researchers at Dana-Farber Cancer Institute and allied institutions reported at the 2013 annual meeting of the American Society of Hematology (ASH). The finding may open the way to clinical trials of the drug in Waldenstrom's patients whose tumor cells carry the mutation.Waldenstrom's is a form of non-Hodgkin lymphoma diagnosed in 2,000 to 3,000 people in the United States each year. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 11, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

Gene 'driver' of Waldenstrom's Macroglobulinemia in up to one-third of patients identified
(Dana-Farber Cancer Institute) In nearly one-third of patients with Waldenstrom's Macroglobulinemia, a specific genetic mutation switches on the disease, and a new drug that blocks the defective gene can arrest the disease in animal models, researchers at Dana-Farber Cancer Institute and allied institutions will report at the 2013 annual meeting of the American Society of Hematology. The finding may open the way to clinical trials of the drug in Waldenstrom's patients whose tumor cells carry the mutation. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 9, 2013 Category: Global & Universal Source Type: news

Pharmacyclics reports results of Ibrutinib Phase II study for Waldenstrom's Macroglobulinemia
Clinical-stage biopharmaceutical company Pharmacyclics has announced results from Phase II study of oral Bruton's tyrosine kinase (BTK) inhibitor, Ibrutinib, conducted in patients with Waldenstrom's Macroglobulinemia (WM). (Source: Drug Development Technology)
Source: Drug Development Technology - June 20, 2013 Category: Pharmaceuticals Source Type: news

FDA grants 'Breakthrough Therapy Designation' to ibrutinib for treatment of relapsed or refractory mantle cell lymphoma and Waldenstrom's macroglobulinemia
Source: BioSpace , PharmaTimes Area: News The FDA has granted 'Breakthrough Therapy Designation' to ibrutinib (as monotherapy) for the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL) and for the treatment of patients with Waldenstrom's macroglobulinemia (WM).   Ibrutinib is an investigational oral agent designed to specifically target and selectively inhibit an enzyme called Bruton's tyrosine kinase (BTK), a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel regulating apoptosis, adhesion, and cell migration and homing.   The Breakthr...
Source: NeLM - News - February 14, 2013 Category: Drugs & Pharmacology Source Type: news